title: Central cannabinoid 1 receptor antagonist administration prevents endotoxic hypotension affecting norepinephrine release in the preoptic anterior hypothalamic area.
abstract: It is widely assumed that LPS lowers arterial pressure during sepsis by stimulating release of TNF-alpha and other vasoactive mediators from macrophages. However, recent data from this and other laboratories have shown that LPS hypotension can be prevented by inhibiting afferent impulse flow in the vagus nerve, by blocking neuronal activity in the nucleus of the solitary tract, or by blocking alpha-adrenergic receptors in the preoptic area/anterior hypothalamic area (POA). These findings suggest that the inflammatory signal is conveyed from the periphery to the brain via the vagus nerve, and that endotoxic shock is mediated through a central mechanism that requires activation of POA neurons. In the present study, we tested whether central cannabinoid 1 (CB1) receptors participate in the control of arterial pressure during endotoxemia based on evidence that hypothalamic neurons express CB1 receptors and synthesize the endogenous CB anandamide. We found that intracerebroventricular administration of rimonabant, a CB1 receptor antagonist, inhibited the fall in arterial pressure evoked by LPS significantly in both conscious and anesthetized rats. Rimonabant attenuated both the immediate fall in arterial pressure evoked by LPS and the second, delayed hypotensive phase that leads to tissue ischemia and death. Rimonabant also prevented the associated LPS-induced rise in extracellular fluid norepinephrine concentrations in the POA. Furthermore, rimonabant attenuated the associated increase in plasma TNF-alpha concentrations characteristic of the late phase of endotoxic hypotension. These data indicate that central CB1 receptors may play an important role in the initiation of endotoxic hypotension.
authors.affiliation: Department of Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, Albany, New York 12208, USA.
authors.forename: Alex
authors.initials: A
authors.lastname: Villanueva
authors.forename: Sertac M
authors.initials: SM
authors.lastname: Yilmaz
authors.forename: William R
authors.initials: WR
authors.lastname: Millington
authors.forename: Rodolfo A
authors.initials: RA
authors.lastname: Cutrera
authors.forename: David G
authors.initials: DG
authors.lastname: Stouffer
authors.forename: Loren H
authors.initials: LH
authors.lastname: Parsons
authors.forename: Joseph F
authors.initials: JF
authors.lastname: Cheer
authors.forename: Carlos
authors.initials: C
authors.lastname: Feleder
mesh_terms: D000818:Animals; D007025:Anterior Hypothalamic Nucleus / Q000187:drug effects* / Q000503:physiopathology; D001095:Arachidonic Acids / Q000494:pharmacology; D001794:Blood Pressure; D063388:Endocannabinoids; D004731:Endotoxins / Q000378:metabolism*; D007022:Hypotension / Q000188:drug therapy / Q000517:prevention & control*; D008070:Lipopolysaccharides / Q000378:metabolism; D008264:Macrophages / Q000378:metabolism; D008297:Male; D009474:Neurons / Q000378:metabolism; D009638:Norepinephrine / Q000378:metabolism*; D010880:Piperidines / Q000494:pharmacology; D053284:Polyunsaturated Alkamides / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors*; D000077285:Rimonabant; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D001095:Arachidonic Acids; D063388:Endocannabinoids; D004731:Endotoxins; D008070:Lipopolysaccharides; D010880:Piperidines; D053284:Polyunsaturated Alkamides; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D014409:Tumor Necrosis Factor-alpha; D000077285:Rimonabant; C078814:anandamide; D009638:Norepinephrine